Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma.
Dermatol Ther
; 35(8): e15634, 2022 08.
Article
em En
| MEDLINE
| ID: mdl-35695215
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Linfoma Cutâneo de Células T
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article